Krystal Biotech Will Update Candidate Data Development

Krystal Biotech (NASDAQ:KRYS) announced the presentation of clinical data for three of its products.

As quoted in the press release:

Krystal Biotech a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis bullosa, and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome on May 9, 2019 at the Society for Investigative Dermatology 77th Annual Meeting in Chicago.

Pooja Agarwal, Ph.D., vice president of product development for Krystal Biotech will present preclinical data for KB105, an investigational topical gene therapy to treat autosomal recessive congenital ichthyosis (ARCI), between 1:30 p.m. – 4 p.m. CDT. During her presentation entitled “Preclinical safety and pharmacology of KB105, an HSV-based gene therapy vector for the treatment of autosomal recessive congenital ichthyosis (ARCI),” Dr. Agarwal will share data from investigational new drug (IND) enabling studies that support an IND filing by Krystal Biotech, expected 2Q 2019.

Click here to read the full press release.